Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Renalytix plc (RNLX) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/30/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"About Chronic Kidney Disease Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The Centers for Disease Control and Prevention estimates that 15% of US adults, more than 38 million people, currently have chronic kidney disease . Diabetes is the leading cause of kidney failure, accounting for 44% of new cases. Further, the CDC reports that 9 out of 10 adults with CKD do not know they have it and one out of two people with very low kidney function who are not on dialysis do not know they have CKD.1 Kidney disease is referred to as a "silent killer" because it often has no symptoms and can go undetected until a very advanced stage. Each year, kidney disease kills more people than breast and prostate cancer. Every day, 13 patients i..."
06/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
06/09/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"General Meeting attendance The general meeting will be held on 8 June 2023 at 3:00 p.m. . The General Meeting will be held at 6 Stratton Street Mayfair, London W1J 8LD. This letter does not contain the full details of the resolutions to be tabled at the General Meeting but these are contained in the Notice of General Meeting and should be read before you complete your vote. The Directors consider that the proposed resolutions contained in the Notice of General Meeting are in the best interests of the Company and shareholders as a whole and unanimously recommend that you vote in favour of them, as they intend to do in respect of their own shareholdings. Proxy voting You will not receive a hard copy form of proxy for the General Meeting in the post. Instead, you will be able to vote electron...",
"RENALYTIX PLC Notice of General Meeting No person should construe the contents of this document as legal, tax or financial advice and recipients of this document should consult their own advisers as to the matters described in this document. This document should be read as a whole. Your attention is drawn to the letter from Christopher Mills, the Non-Executive Chairman of the Company, on pages 5 to 7 of this document in which the Directors recommend that you vote in favour of each of the Resolutions to be proposed at the General Meeting referred to below. Cautionary note regarding forward-looking statements: This document contains statements about the Company that are or may be “forward-looking statements”. All statements, other than statements of historical facts, included i..."
05/11/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix plc Notice of General Meeting and Posting of Circular LONDON and SALT LAKE CITY, May 11, 2023 - Renalytix announces that a circular containing a notice convening a General Meeting to be held at the offices of Harwood Capital LLP, 6 Stratton Street Mayfair, London W1J 8LD at 3 p.m. on 8 June 2023, has today been posted to the Company’s shareholders. An electronic copy of the circular will shortly be available on the Company’s website at www.renalytix.com in accordance with AIM Rule 20. For further information, please contact: Renalytix plc www.renalytix.com James McCullough, CEO Via Walbrook PR Stifel Tel: 020 7710 7600 Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea Investec Bank plc Tel: 020 7597 4000 Gary Clarence / Shalin Bhamra Walbrook PR Limited Tel: 020 7933..."
03/30/2023 6-K Quarterly results
03/27/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/21/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
03/10/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
02/08/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix plc Renalytix announces a c.$20.3 million private placement LONDON and SALT LAKE CITY, February 8, 2023 -- Renalytix plc announces a c.$20.3 million private placement of Ordinary Shares and American Depositary Shares .",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 7, 2023 , by and among Renalytix plc, a public limited company incorporated under the laws of England and Wales , and each purchaser identified on the signature pages hereto . Whereas, the Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Regulation S promulgated under the Securities Act of 1933, as amended , solely to prospective investors in the United Kingdom. Whereas, each Purchaser wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, ordinary shares, nominal value £0.0025 per share , in the numbers set forth opposite such Purchaser’s name on hereto . T...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of February 7, 2023 , by and among Renalytix plc, a public limited company incorporated under the laws of England and Wales , and each purchaser identified on the signature pages hereto . Whereas, the Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended , solely to prospective investors in the United States. Whereas, each Purchaser wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, American Depositary Shares , each representing two ordinary shares, nominal value £0.0025 per share , in the numbers set forth opposite suc...",
"REGISTRATION RIGHTS AGREEMENT by and between The Hamilton E. James 2003 Childrens Trust and Renalytix plc ___________________________________ Dated as of February 6, 2023 Table of Contents Page 1. Certain Definitions. 1 2. Shelf Registration Statement. 3 3. Piggyback Registrations. 4 4. Other Registrations 5 5. Selection of Underwriters. 5 6. Procedures. 5 7. Registration Expenses. 9 8. Board Appointment. 10 9. Indemnification. 12 10. Term of Agreement. 13 11. Transfer of Registration Rights. 14 12. Conversion or Exchange of Other Securities. 14 13. Miscellaneous. 14 i Registration Rights Agreement dated as of February 6, 2023, by and between Renalytix plc, incorporated and registered in England and Wales with company number 11257655 , and The Hamilton E. James 2003 Childrens Trust , and f..."
12/20/2022 6-K Quarterly results
11/30/2022 6-K Quarterly results
11/29/2022 6-K Quarterly results
11/22/2022 6-K Quarterly results
10/25/2022 6-K Quarterly results
09/21/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix plc Renalytix Announces Change to Board of Directors LONDON and SALT LAKE CITY, 20 September 2022 – Renalytix plc announces that Ann Berman, non-executive director and chair of the audit and nomination committees, has resigned as a director of the Company for personal reasons effective immediately. Ms. Berman commented, “I regret that I am unable to continue in my capacity as non-executive director of Renalytix, which for personal and family reasons, has become impractical. I remain highly encouraged by the Company’s recent progress in reimbursement, regulatory and commercial milestones and believe KidneyIntelX holds the key to solving some of the intractable problems associated with patient suffering and cost related to diabetes and kidney disease.” Christopher Mi..."
08/17/2022 6-K Quarterly results
06/30/2022 6-K Quarterly results
06/27/2022 6-K Quarterly results
04/01/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix plc Renalytix announces a $30.0 million financing package NEW YORK and SALT LAKE CITY, March 31, 2022 – Renalytix Plc announces pricing of a $30.0 million financing package ."
03/31/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix plc Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2022 LONDON and SALT LAKE CITY, March 31, 2022 – Renalytix plc , an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the quarter ended December 31, 2021. Recent Highlights • Quarter over quarter growth in KidneyIntelX testing volume • Quarter over quarter growth in active physicians ordering KidneyIntelX • KidneyIntelX now on-line with the Veterans Administration health system , New York physician led payor program CDPHP, Wake Forest Baptist Health and Atrium Health system • Singing River Health System partn..."
12/20/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K"
12/07/2021 6-K Quarterly results
11/30/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Annual Report and Financial Statements for the year ended June 30, 2021",
"Letter to Shareholders",
"Notice of Annual General Meeting",
"Form of Proxy"
10/21/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix plc Renalytix Reports Full Year Fiscal 2021 Results"
08/30/2021 6-K Quarterly results
07/28/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix Appoints Ann Berman to its Board of Directors"
07/06/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Death of Director NEW YORK, 1 July, 2021 - The Board of Renalytix plc is saddened to announce the death of Dr. Barbara Murphy, Non-Executive Director and Co-Founder, who passed away on June 29th 2021. Dr. Murphy had continued to fully discharge her duties as a Director through a recent period of illness, however over the past few weeks her health deteriorated. Dr. Murphy was an enthusiastic and inspirational member of the Renalytix family since November 2018. James McCullough, CEO at Renalytix, said: “We are deeply saddened by Barbara's untimely death. Barbara was a world-leading innovator in clinical medicine whose research excellence, unparalleled medical knowledge and kindness as a human being are a terrible loss for patients and the medical community at-large. Personally, I have lost ..."
06/24/2021 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix AI plc Change of name to Renalytix plc Change of registered office Change of website"
06/15/2021 6-K Quarterly results
06/10/2021 6-K Quarterly results
03/02/2021 6-K Quarterly results
12/07/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "6-K",
"Renalytix AI plc Result of AGM"
11/25/2020 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Operational Update and Financial Results for the Three Months Ended September 30, 2020",
"Operational Update and Financial Results for the Three Months Ended September 30, 2020"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy